PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 8(1): 43-47 1988
© 1988 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DiRaimondo, C. R.
Right arrow Articles by Stone, W. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by DiRaimondo, C. R.
Right arrow Articles by Stone, W. J.

REVIEWS AND ORIGINAL ARTICLES

Beta-2 Microglobulin in Peritoneal Dialysis Patients: Serum Levels and Peritoneal Clearances

Carol R. DiRaimondo, Patricia McCarley and William J. Stone

Medical Service (Nephrology), Veterans Administration Medical Center, Nashville, Tennessee

Correspondence to C. R. DiRaimondo's current address: Diablo Nephrology Medical Group, 120 La Casa Via, Suite 211, Walnut Creek, CA 94598.

Beta-2 microglobulin {B2M) is amyloidogenic in long-term hemodialysis patients, with amyloid deposition manifesting as lytic bone lesions, carpal tunnel syndrome, destructive arthropathies, tenosynovitis, and pathologic fractures. To study the behavior of this protein in the peritoneal dialysis population, serum levels of B2M from 14 chronic peritoneal dialysis {CPD) patients {4IPD, 10 CAPD) were compared to those of 15 chronic hemodialysis patients, and peritoneal clearances were measured in 9 CAPD patients. Standard cuprophan dialyzers were used for hemodialysis.

Serum B2M levels were significantly lower in the peritoneal dialysis group {mean ± SD 73.2 ± 20.9 mg/L) than in the hemodialysis group {100.3 ± 24.7 mg/L, p < .004). When CAPD patients alone were compared to the hemodialysis patients, lower serum B2M levels were again apparent, with mean 68.7 ± 16.4 mg/L {p &le; .002). Mean serum B2M in IPD patients {84.6 ± 28.9 mg/L) did not differ statistically from either the CAPD or the hemodialysis group.

Peritoneal clearance of B2M, urea nitrogen, and creatinine over a 6 h exchange were obtained in 9 CAPD patients without peritonitis. Mean clearance {±SD) of B2M was 0.9 ± 0.4 ml/min/1.73 m2, urea nitrogen 5.3 ± 0.3 ml/min/1.73 m2, and creatinine 4.2 ± 0.8 ml/min/1.73 m2. Mean loss of B2M via the peritoneal cavity was 19.9 ± 6.6 mg/2 L-exchange/1.73 m2 {range 7.7 to 26.2 mg/2 L-exchange/1.73 m2).

Decreased serum B2M in peritoneal dialysis patients is consistent with increased clearance by the peritoneal membrane versus standard cellulosic hemodialysis membranes. Whether use of CPD rather than hemodialysis can prevent or even treat dialysis-associated amyloidosis {AB2M) remains speculative.

KEY WORDS: Beta-2 microglobulin; peritoneal dialysis; continuous ambulatory peritoneal dialysis (CAPD); amyloidosis; dialysis-associated amyloidosis.

Received 24 July 1987; accepted 1 October 1987.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 1988 by Multimed Inc.